Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

2.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

3.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
4.

Long-term consequences of Hodgkin lymphoma therapy on T-cell lymphopoiesis.

Pellier I, Renier G, Rakotonjanahary J, Audrain M, Berardi E, Gardembas M, Clavert A, Moles MP, Proust-Houdemont S, Reguerre Y, De Carli E, Georgin-Mege M, Garo E, Blanchard S, Miot C, Picard C, Delneste Y, Fischer A, Tanguy-Schmidt A, Jeannin P.

J Allergy Clin Immunol. 2015 Mar;135(3):818-20.e4. doi: 10.1016/j.jaci.2014.08.048. Epub 2014 Oct 25. No abstract available.

PMID:
25420683
5.

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S.

Ann Hematol. 2014 Feb;93(2):233-42. doi: 10.1007/s00277-013-1860-8.

PMID:
24563925
6.

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S.

Ann Hematol. 2014 Feb;93(2):233-42. doi: 10.1007/s00277-013-1860-8. Epub 2013 Aug 16.

PMID:
23949376
7.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M.

Ann Oncol. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.

PMID:
22440229
8.

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.

Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, Bouabdallah K, Alexis Vigier M, Moles MP, Tournilhac O, Arakelyan N, Rodon P, El Yamani A, Sutton L, Fornecker L, Assouline D, Harousseau JL, Maisonneuve H, Caulet-Maugendre S, Gressin R; French GOELAMS group.

Ann Oncol. 2012 Jun;23(6):1555-61. doi: 10.1093/annonc/mdr450. Epub 2011 Oct 19.

PMID:
22012966
9.

Induction-related cost of patients with acute myeloid leukaemia in France.

Nerich V, Lioure B, Rave M, Recher C, Pigneux A, Witz B, Escoffre-Barbe M, Moles MP, Jourdan E, Cahn JY, Woronoff-Lemsi MC.

Int J Clin Pharm. 2011 Apr;33(2):191-9. doi: 10.1007/s11096-010-9462-1. Epub 2011 Jan 28.

PMID:
21744189
10.

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.

Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC.

Histopathology. 2010 May;56(6):758-67. doi: 10.1111/j.1365-2559.2010.03545.x.

PMID:
20546341
11.

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group.

Haematologica. 2010 Aug;95(8):1350-7. doi: 10.3324/haematol.2009.011759. Epub 2010 Mar 10.

12.

[Bortezomib-induced acute neutrophilic dermatosis].

Tanguy-Schmidt A, Avenel-Audran M, Croué A, Lissandre S, Dib M, Zidane-Marinnes M, Moles MP, Hunault-Berger M.

Ann Dermatol Venereol. 2009 May;136(5):443-6. doi: 10.1016/j.annder.2008.11.021. Epub 2009 Apr 28. French.

PMID:
19442803
13.

Disseminated nasal-type natural killer/T-cell lymphoma in a child: a case report.

Pellier I, N'Golet L, Rachieru P, Rousselet MC, Geneviève F, Moles MP, Hermine O, Rialland X.

J Pediatr Hematol Oncol. 2009 May;31(5):362-6. doi: 10.1097/MPH.0b013e3181998346.

PMID:
19415021
14.
15.

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M; Société Française de Greffe de Moëlle et de Thérapie Cellulaire.

J Clin Oncol. 2008 May 10;26(14):2264-71. doi: 10.1200/JCO.2007.14.1366. Epub 2008 Apr 7.

PMID:
18390969
16.
17.

Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.

Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M, Jeannin P.

Blood. 2007 Dec 15;110(13):4319-30. Epub 2007 Sep 11.

18.

[Hypercalcaemia and malignant lymphoma. One case report].

Frein D, Lavigne C, Josselin N, Foussard C, Sivova N, Moles MP, Berrut G.

Rev Med Interne. 2007 Oct;28(10):714-5. Epub 2007 May 22. French.

PMID:
17544176
19.

[Tumor like presentation of primitive amyloidosis: amyloidoma].

Moles MP, Brousseau M, Rachieru AP, Godon A, Schmidt A, Furber A, Rousselet MC, Hunault-Berger M.

Rev Med Interne. 2007 May;28(5):339-42. Epub 2007 Jan 26. French.

PMID:
17360073
20.

[Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].

Moles MP, Landry J, Roche-Lestienne C, Godon A, Schmidt-Tanguy A, Gardembas M, Le Clech C, Verret JL, Zandecki M, Blanchet O.

Ann Biol Clin (Paris). 2005 May-Jun;63(3):317-22. French.

Supplemental Content

Loading ...
Support Center